Movement Alert｜Giant Biogene Rises 5.08% in Regular Trading, Medical Aesthetics Dual Certification and Strong 618 Performance Drive Rebound

Market Focus07-10

On July 10, Giant Biogene rose 5.08% in regular trading, trading at HKD 26.4/share, with turnover of approximately HKD 58.35 million.

On the news front, multiple brokerages recently published June cosmetics monthly reports highlighting the accelerated expansion of Giant Biogene's medical aesthetics matrix. The company has become the world's first enterprise simultaneously holding registration certificates for both recombinant Type I and Type III collagen medical aesthetic implants. Its subsidiary obtained approval for a crosslinked recombinant collagen implant featuring a full-length 1,068 amino acid sequence of human Type III collagen, targeting moderate-to-severe neck wrinkles.

Additionally, during the 618 shopping festival, the company's core brand Kefu Mei recorded over 40% year-over-year GMV growth on its Douyin channel, signaling stabilization of its brand fundamentals. Brokerages including CICC, Dongfang Securities, and Guotai Haitong have maintained positive ratings, with target prices ranging from HKD 40 to HKD 43, citing the company's medical aesthetics commercialization and skincare business recovery as key catalysts.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1103423845?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 10:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103423845","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Giant Biogene Rises 5.08% in Regular Trading, Medical Aesthetics Dual Certification and Strong 618 Performance Drive Rebound","media":"Market Focus","content":"<p><p>On July 10, Giant Biogene rose 5.08% in regular trading, trading at HKD 26.4/share, with turnover of approximately HKD 58.35 million.</p><p>On the news front, multiple brokerages recently published June cosmetics monthly reports highlighting the accelerated expansion of Giant Biogene's medical aesthetics matrix. The company has become the world's first enterprise simultaneously holding registration certificates for both recombinant Type I and Type III collagen medical aesthetic implants. Its subsidiary obtained approval for a crosslinked recombinant collagen implant featuring a full-length 1,068 amino acid sequence of human Type III collagen, targeting moderate-to-severe neck wrinkles.</p><p>Additionally, during the 618 shopping festival, the company's core brand Kefu Mei recorded over 40% year-over-year GMV growth on its Douyin channel, signaling stabilization of its brand fundamentals. Brokerages including CICC, Dongfang Securities, and Guotai Haitong have maintained positive ratings, with target prices ranging from HKD 40 to HKD 43, citing the company's medical aesthetics commercialization and skincare business recovery as key catalysts.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Giant Biogene Rises 5.08% in Regular Trading, Medical Aesthetics Dual Certification and Strong 618 Performance Drive Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Giant Biogene Rises 5.08% in Regular Trading, Medical Aesthetics Dual Certification and Strong 618 Performance Drive Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-10 10:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 10, Giant Biogene rose 5.08% in regular trading, trading at HKD 26.4/share, with turnover of approximately HKD 58.35 million.</p><p>On the news front, multiple brokerages recently published June cosmetics monthly reports highlighting the accelerated expansion of Giant Biogene's medical aesthetics matrix. The company has become the world's first enterprise simultaneously holding registration certificates for both recombinant Type I and Type III collagen medical aesthetic implants. Its subsidiary obtained approval for a crosslinked recombinant collagen implant featuring a full-length 1,068 amino acid sequence of human Type III collagen, targeting moderate-to-severe neck wrinkles.</p><p>Additionally, during the 618 shopping festival, the company's core brand Kefu Mei recorded over 40% year-over-year GMV growth on its Douyin channel, signaling stabilization of its brand fundamentals. Brokerages including CICC, Dongfang Securities, and Guotai Haitong have maintained positive ratings, with target prices ranging from HKD 40 to HKD 43, citing the company's medical aesthetics commercialization and skincare business recovery as key catalysts.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02367","symbol_name":"巨子生物","start_time":0,"source_url":"","article_id":"1103423845","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103423845","pubTimestamp":1783650770,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 10, Giant Biogene rose 5.08% in regular trading, trading at HKD 26.4/share, with turnover of approximately HKD 58.35 million.On the news front, multiple brokerages recently published June...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02367":"巨子生物"},"translate_title":"走势预警|巨人百健常规交易大涨5.08%，医美双认证和618强劲业绩驱动反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02367":1},"content_text":"On July 10, Giant Biogene rose 5.08% in regular trading, trading at HKD 26.4/share, with turnover of approximately HKD 58.35 million.On the news front, multiple brokerages recently published June cosmetics monthly reports highlighting the accelerated expansion of Giant Biogene's medical aesthetics matrix. The company has become the world's first enterprise simultaneously holding registration certificates for both recombinant Type I and Type III collagen medical aesthetic implants. Its subsidiary obtained approval for a crosslinked recombinant collagen implant featuring a full-length 1,068 amino acid sequence of human Type III collagen, targeting moderate-to-severe neck wrinkles.Additionally, during the 618 shopping festival, the company's core brand Kefu Mei recorded over 40% year-over-year GMV growth on its Douyin channel, signaling stabilization of its brand fundamentals. Brokerages including CICC, Dongfang Securities, and Guotai Haitong have maintained positive ratings, with target prices ranging from HKD 40 to HKD 43, citing the company's medical aesthetics commercialization and skincare business recovery as key catalysts.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103423845","isCrawlerRequest":true}